Sotwe logo Sotwe logo
fintchone's profile banner image
fintchone's profile image

Fintch

Verified account

@fintchone

IPO & private deals for serious investors. Institutional-style allocation, on-chain yield & pools.
Joined September 2024
40 Following
528 Followers
252 Posts
fintchone's profile image
Fintch Verified account @fintchone
🏦 New IPO: Forbright (#FRBT) A new IPO is now available in the Fintch app. Forbright is a digital banking holding company and asset manager headquartered in Chevy Chase, Maryland. Traces its history to Congressional Bank, founded in 2003, rebranded as Forbright Bank in 2022. A fully licensed Maryland-chartered, FDIC-insured bank combining three businesses: specialty middle-market lending, a digital consumer deposit platform (Forbright Growth Savings), and strategic advisory/asset management (Alliance Partners). Total assets grew from $1.9B (Dec 31, 2020) to $8.2B (March 31, 2026) - a 4.3x increase in five years. CEO and founder is John Delaney, a two-time financial services IPO entrepreneur and former US Congressman from Maryland (2013-2019). Bet on: the only publicly traded bank combining focused middle-market specialty lending + a digital-only national deposit franchise ($3.9B, ~95,000 accounts) with no branch network + ESG/sustainability positioning as a differentiator + collateral-intensive first-lien loan structures across five verticals (healthcare, lender, fund, real estate, corporate finance) that reduce credit risk + cost-efficient digital deposit funding + capital-light Alliance Partners fee income with no balance sheet risk + $369M 2021 equity infusion from Centerbridge, Gallatin Point Capital, and Bayview Asset Management + anchor IPO investor Horizon Kinetics. 📊 Key terms - Price range: $18-20 per share - Shares offered: 7,900,000 Class A (plus overallotment of up to 1,185,000) - Net proceeds to company at midpoint $19: ~$138.2M - Market cap: ~$993.8M at top of range - Exchange: Nasdaq Global Select Market | Ticker: FRBT - Pricing: June 10, 2026 | Trading: June 11, 2026 - Lock-up: 93 days 💰 Financials - Total assets March 31, 2026: $8.2B (+331% from $1.9B in 2020) - LTM revenue (12 months to March 31, 2026): $334M - FY2025 net income: $87.9M (up from $12.2M in 2020 - 7.2x in five years) - Digital deposits: $3.9B (~47.6% of total assets) across ~95,000 accounts - Valuation: ~$993.8M market cap at top of range - P/Book ~1.0x; P/E ~11.3x - a moderate multiple for a fast-growing specialty bank - Structure: mixed - primary shares ($138.2M net proceeds, directed to loan portfolio growth) + secondary shares from selling stockholders 🎯 Thesis Four mutually reinforcing businesses: core banking credit (first-lien middle-market loans), the Forbright Growth Savings digital deposit platform (a cost-efficient funding source with no retail branch network), capital-light Alliance Partners advisory/loan distribution, and a "green bank" sustainability tilt toward clean energy and sustainable construction - one of few FDIC-insured banks to build clean-energy lending as a meaningful vertical. The US specialty middle-market lending market is among the most profitable in private credit for banks with niche expertise; structural tailwinds include healthcare sector growth, private equity expansion (fund finance demand), and the gap left by regional banks exiting certain niches. Direct comparables: Western Alliance (WAL), Triumph Financial, Customers Bancorp (CUBI), Live Oak Bancshares (LOAK). The triple combination of specialty lending + national digital-deposit franchise + ESG is unique among US public banks. Key risk: credit cycle exposure in middle-market lending, deposit-cost sensitivity, and CRE concentration. 🏛️ Joint lead bookrunners: Goldman Sachs, J.P. Morgan, Barclays. Additional bookrunners: Citizens JMP, Hovde Group, Janney Montgomery Scott, Piper Sandler, Raymond James, Stifel, Truist Securities, Wells Fargo Securities. 📅 Deadline: June 10, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GQldg
fintchone's tweet photo. 🏦 New IPO: Forbright (#FRBT) A new IPO is now available in the Fintch app. Forbright is a digital banking holding company and asset manager headquartered in Chevy Chase, Maryland. Traces its history to Congressional Bank, founded in 2003, rebranded as Forbright Bank in 2022. A fully licensed Maryland-chartered, FDIC-insured bank combining three businesses: specialty middle-market lending, a digital consumer deposit platform (Forbright Growth Savings), and strategic advisory/asset management (Alliance Partners). Total assets grew from $1.9B (Dec 31, 2020) to $8.2B (March 31, 2026) - a 4.3x increase in five years. CEO and founder is John Delaney, a two-time financial services IPO entrepreneur and former US Congressman from Maryland (2013-2019). Bet on: the only publicly traded bank combining focused middle-market specialty lending + a digital-only national deposit franchise ($3.9B, ~95,000 accounts) with no branch network + ESG/sustainability positioning as a differentiator + collateral-intensive first-lien loan structures across five verticals (healthcare, lender, fund, real estate, corporate finance) that reduce credit risk + cost-efficient digital deposit funding + capital-light Alliance Partners fee income with no balance sheet risk + $369M 2021 equity infusion from Centerbridge, Gallatin Point Capital, and Bayview Asset Management + anchor IPO investor Horizon Kinetics. 📊 Key terms - Price range: $18-20 per share - Shares offered: 7,900,000 Class A (plus overallotment of up to 1,185,000) - Net proceeds to company at midpoint $19: ~$138.2M - Market cap: ~$993.8M at top of range - Exchange: Nasdaq Global Select Market | Ticker: FRBT - Pricing: June 10, 2026 | Trading: June 11, 2026 - Lock-up: 93 days 💰 Financials - Total assets March 31, 2026: $8.2B (+331% from $1.9B in 2020) - LTM revenue (12 months to March 31, 2026): $334M - FY2025 net income: $87.9M (up from $12.2M in 2020 - 7.2x in five years) - Digital deposits: $3.9B (~47.6% of total assets) across ~95,000 accounts - Valuation: ~$993.8M market cap at top of range - P/Book ~1.0x; P/E ~11.3x - a moderate multiple for a fast-growing specialty bank - Structure: mixed - primary shares ($138.2M net proceeds, directed to loan portfolio growth) + secondary shares from selling stockholders 🎯 Thesis Four mutually reinforcing businesses: core banking credit (first-lien middle-market loans), the Forbright Growth Savings digital deposit platform (a cost-efficient funding source with no retail branch network), capital-light Alliance Partners advisory/loan distribution, and a "green bank" sustainability tilt toward clean energy and sustainable construction - one of few FDIC-insured banks to build clean-energy lending as a meaningful vertical. The US specialty middle-market lending market is among the most profitable in private credit for banks with niche expertise; structural tailwinds include healthcare sector growth, private equity expansion (fund finance demand), and the gap left by regional banks exiting certain niches. Direct comparables: Western Alliance (WAL), Triumph Financial, Customers Bancorp (CUBI), Live Oak Bancshares (LOAK). The triple combination of specialty lending + national digital-deposit franchise + ESG is unique among US public banks. Key risk: credit cycle exposure in middle-market lending, deposit-cost sensitivity, and CRE concentration. 🏛️ Joint lead bookrunners: Goldman Sachs, J.P. Morgan, Barclays. Additional bookrunners: Citizens JMP, Hovde Group, Janney Montgomery Scott, Piper Sandler, Raymond James, Stifel, Truist Securities, Wells Fargo Securities. 📅 Deadline: June 10, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GQldg
0
0
0
0
82
fintchone's profile image
Fintch Verified account @fintchone
🧬 New IPO: Parabilis Medicines (#PBLS) A new IPO is now available in the Fintch app. Parabilis Medicines (formerly FogPharma) is a Cambridge, Massachusetts clinical-stage biopharmaceutical company founded in 2015. Develops Helicons - a novel class of stabilized, cell-penetrant alpha-helical peptides engineered to bind flat protein-protein interaction surfaces historically considered "undruggable". Over 10+ years has built a platform combining proprietary data, lab innovations, and AI/physics-based algorithms. CEO, Chairman, and President is Mathai Mammen, M.D., Ph.D., formerly Global Head of R&D at Johnson & Johnson. 200+ employees. Bet on: lead candidate zolucatetide (formerly FOG-001) - the world's first direct inhibitor of the β-catenin:TCF protein-protein interaction, the critical node of the Wnt/β-catenin pathway whose mutations appear in 30-40% of all cancers + clinical activity confirmed in 150+ patients in Phase 1/2 + desmoid tumors program with FDA Fast Track (Nov 2025) and FDA Orphan Drug Designation (March 2026), Phase 3 planned H1 2027 + Helicons solve three problems at once: large enough for flat PPI surfaces, small enough to penetrate cells, stable enough to resist degradation + Regeneron strategic collaboration (May 2026) worth up to $2.3B + the only publicly-traded clinical company in the stabilized cell-penetrant peptide segment with proven human activity. 📊 Key terms - Price range: $17-19 per share - Shares offered: 25,000,000 - IPO net proceeds to company: ~$413.6M at midpoint $18 - Exchange: Nasdaq Global Market | Ticker: PBLS - Pricing: June 9, 2026 | Trading: June 10, 2026 - Lock-up: 93 days 💰 Financials - Revenue: $0 - clinical stage, no commercial sales - Last private round (January 2026): $305M - oversubscribed - Regeneron partnership: $50M upfront + $75M equity in the IPO (at 90% of IPO price - a direct partner confidence signal) + up to $2.3B in potential milestones - Total raised over company history: ~$750M+ - IPO proceeds use: Phase 3 zolucatetide in desmoid tumors (launch H1 2027), continuing Phase 1/2 across FAP/HCC and other Wnt-driven tumors, advancing ERG and AR degraders toward Phase 1, β-catenin degrader program, Helicon platform, general corporate purposes 🎯 Thesis Desmoid tumors are an ultra-rare neoplasm with ~3,500 new US cases annually and no standard of care - the first approved targeted therapy holds a near-monopoly position. Beyond desmoid, the Wnt/β-catenin pathway is active in 30-40% of all cancers, making a successful β-catenin inhibitor potentially transformative across oncology - a market measured in tens of billions. Additional Phase 1/2 signals: FAP (52.2% desmoid diameter reduction plus polyp burden reduction), HCC (9-month partial response in a CTNNB1-mutant patient), MSS colorectal, ACP, and more. No direct analogs for zolucatetide - β-catenin was called a "Holy Grail" and "undruggable" since the early 1990s. Indirect desmoid competitors: sotorasib, nivolumab/immunotherapy. Cell-penetrant peptide peers (CellForce, Aileron) are earlier-stage and smaller. Key risk: $0 revenue, binary clinical/regulatory outcomes, capital-intensive Phase 3 runway. 🏛️ Joint lead bookrunners: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities. Bookrunner: LifeSci Capital. 📅 Deadline: June 9, 2026 (inclusive) 📲 Explore the deal in the Fintch app: Download https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🧬 New IPO: Parabilis Medicines (#PBLS) A new IPO is now available in the Fintch app. Parabilis Medicines (formerly FogPharma) is a Cambridge, Massachusetts clinical-stage biopharmaceutical company founded in 2015. Develops Helicons - a novel class of stabilized, cell-penetrant alpha-helical peptides engineered to bind flat protein-protein interaction surfaces historically considered "undruggable". Over 10+ years has built a platform combining proprietary data, lab innovations, and AI/physics-based algorithms. CEO, Chairman, and President is Mathai Mammen, M.D., Ph.D., formerly Global Head of R&D at Johnson & Johnson. 200+ employees. Bet on: lead candidate zolucatetide (formerly FOG-001) - the world's first direct inhibitor of the β-catenin:TCF protein-protein interaction, the critical node of the Wnt/β-catenin pathway whose mutations appear in 30-40% of all cancers + clinical activity confirmed in 150+ patients in Phase 1/2 + desmoid tumors program with FDA Fast Track (Nov 2025) and FDA Orphan Drug Designation (March 2026), Phase 3 planned H1 2027 + Helicons solve three problems at once: large enough for flat PPI surfaces, small enough to penetrate cells, stable enough to resist degradation + Regeneron strategic collaboration (May 2026) worth up to $2.3B + the only publicly-traded clinical company in the stabilized cell-penetrant peptide segment with proven human activity. 📊 Key terms - Price range: $17-19 per share - Shares offered: 25,000,000 - IPO net proceeds to company: ~$413.6M at midpoint $18 - Exchange: Nasdaq Global Market | Ticker: PBLS - Pricing: June 9, 2026 | Trading: June 10, 2026 - Lock-up: 93 days 💰 Financials - Revenue: $0 - clinical stage, no commercial sales - Last private round (January 2026): $305M - oversubscribed - Regeneron partnership: $50M upfront + $75M equity in the IPO (at 90% of IPO price - a direct partner confidence signal) + up to $2.3B in potential milestones - Total raised over company history: ~$750M+ - IPO proceeds use: Phase 3 zolucatetide in desmoid tumors (launch H1 2027), continuing Phase 1/2 across FAP/HCC and other Wnt-driven tumors, advancing ERG and AR degraders toward Phase 1, β-catenin degrader program, Helicon platform, general corporate purposes 🎯 Thesis Desmoid tumors are an ultra-rare neoplasm with ~3,500 new US cases annually and no standard of care - the first approved targeted therapy holds a near-monopoly position. Beyond desmoid, the Wnt/β-catenin pathway is active in 30-40% of all cancers, making a successful β-catenin inhibitor potentially transformative across oncology - a market measured in tens of billions. Additional Phase 1/2 signals: FAP (52.2% desmoid diameter reduction plus polyp burden reduction), HCC (9-month partial response in a CTNNB1-mutant patient), MSS colorectal, ACP, and more. No direct analogs for zolucatetide - β-catenin was called a "Holy Grail" and "undruggable" since the early 1990s. Indirect desmoid competitors: sotorasib, nivolumab/immunotherapy. Cell-penetrant peptide peers (CellForce, Aileron) are earlier-stage and smaller. Key risk: $0 revenue, binary clinical/regulatory outcomes, capital-intensive Phase 3 runway. 🏛️ Joint lead bookrunners: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities. Bookrunner: LifeSci Capital. 📅 Deadline: June 9, 2026 (inclusive) 📲 Explore the deal in the Fintch app: Download https://t.co/CqMT1GPNnI
0
0
0
0
57
fintchone's profile image
Fintch Verified account @fintchone
⚡️ New IPO: ERock, Inc (#EROC) A new IPO is now available in the Fintch app. ERock, Inc (formerly Enchanted Rock) is a Houston-based distributed energy company founded in 2006. Designs, manufactures, and operates large-scale onsite natural gas generation systems - branded RockBlock - for data centers, utilities, and industry. 400 operational sites across nine US states, 1,059 MW installed, 2,000 deployed units. Portfolio company of Energy Impact Partners. Bet on: the only standardized onsite-power product (RockBlock, not custom projects) at the intersection of the AI infrastructure boom and the US grid crisis + interconnection queues at 11,700+ GW (LBNL); a large data center waits 3-7 years for grid connection, ERock enables launch in 6-18 months + contracted backlog of $1.28B (+779% YoY), 7x annual revenue + Hyperion campus scaling capacity to ~1.2 GW by year-end 2026 (from ~300-400 MW/year) + mix-shift toward recurring Service and Operating Lease revenue + $1.5B in deployed assets. 📊 Key terms - Price range: $20-23 per Class A share - Class A shares offered: 27,906,977 - Gross proceeds: $558-641.9M base - Market cap: up to ~$5B at top of range - Exchange: NYSE | Ticker: EROC - Pricing: June 9, 2026 | Trading: June 10, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $183.1M (+42.5% YoY from $128.5M in 2024) - Q1 2026 revenue: $31.7M (+31.6% YoY) - FY2025 GAAP net loss: $59M (from ~$30M in 2024) | Q1 2026 net loss: $17.2M - Backlog March 31, 2026: $1.28B (+779% YoY from $146M) - Deployed operational assets: $1.5B (400 sites, 1,059 MW) - Valuation: ~$5B market cap vs $183.1M FY2025 revenue - P/Revenue ~27.3x - Proceeds: Hyperion expansion, RockBlock R&D, backlog working capital - organic growth, not refinancing 🎯 Thesis Three segments: Power System Sales (~60-65% of 2025 revenue), recurring Service Arrangements, and Operating Leases (power-as-a-service). With $1.28B backlog against ~400 MW/year capacity, Hyperion is built to clear a structural production bottleneck. The US onsite generation market runs $3-5B in 2025 toward $15-25B by 2030 on $725B hyperscaler capex - ERock is among the most direct beneficiaries of AI power demand outside GPU makers. Competitors: Cummins (CMI), Caterpillar (CAT), INNIO (INIO), Bloom Energy (BE). No dominant public leader in the niche yet. Key risk: widening GAAP loss, premium ~27.3x multiple, Hyperion ramp execution. 🏛️ Joint lead bookrunners: Morgan Stanley, J.P. Morgan. Joint: Barclays, BofA Securities. Bookrunners: Evercore ISI, Guggenheim Securities, Wolfe | Nomura Alliance, BNP Paribas. 📅 Deadline: June 9, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. ⚡️ New IPO: ERock, Inc (#EROC) A new IPO is now available in the Fintch app. ERock, Inc (formerly Enchanted Rock) is a Houston-based distributed energy company founded in 2006. Designs, manufactures, and operates large-scale onsite natural gas generation systems - branded RockBlock - for data centers, utilities, and industry. 400 operational sites across nine US states, 1,059 MW installed, 2,000 deployed units. Portfolio company of Energy Impact Partners. Bet on: the only standardized onsite-power product (RockBlock, not custom projects) at the intersection of the AI infrastructure boom and the US grid crisis + interconnection queues at 11,700+ GW (LBNL); a large data center waits 3-7 years for grid connection, ERock enables launch in 6-18 months + contracted backlog of $1.28B (+779% YoY), 7x annual revenue + Hyperion campus scaling capacity to ~1.2 GW by year-end 2026 (from ~300-400 MW/year) + mix-shift toward recurring Service and Operating Lease revenue + $1.5B in deployed assets. 📊 Key terms - Price range: $20-23 per Class A share - Class A shares offered: 27,906,977 - Gross proceeds: $558-641.9M base - Market cap: up to ~$5B at top of range - Exchange: NYSE | Ticker: EROC - Pricing: June 9, 2026 | Trading: June 10, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $183.1M (+42.5% YoY from $128.5M in 2024) - Q1 2026 revenue: $31.7M (+31.6% YoY) - FY2025 GAAP net loss: $59M (from ~$30M in 2024) | Q1 2026 net loss: $17.2M - Backlog March 31, 2026: $1.28B (+779% YoY from $146M) - Deployed operational assets: $1.5B (400 sites, 1,059 MW) - Valuation: ~$5B market cap vs $183.1M FY2025 revenue - P/Revenue ~27.3x - Proceeds: Hyperion expansion, RockBlock R&D, backlog working capital - organic growth, not refinancing 🎯 Thesis Three segments: Power System Sales (~60-65% of 2025 revenue), recurring Service Arrangements, and Operating Leases (power-as-a-service). With $1.28B backlog against ~400 MW/year capacity, Hyperion is built to clear a structural production bottleneck. The US onsite generation market runs $3-5B in 2025 toward $15-25B by 2030 on $725B hyperscaler capex - ERock is among the most direct beneficiaries of AI power demand outside GPU makers. Competitors: Cummins (CMI), Caterpillar (CAT), INNIO (INIO), Bloom Energy (BE). No dominant public leader in the niche yet. Key risk: widening GAAP loss, premium ~27.3x multiple, Hyperion ramp execution. 🏛️ Joint lead bookrunners: Morgan Stanley, J.P. Morgan. Joint: Barclays, BofA Securities. Bookrunners: Evercore ISI, Guggenheim Securities, Wolfe | Nomura Alliance, BNP Paribas. 📅 Deadline: June 9, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
1
0
0
70
fintchone's profile image
Fintch Verified account @fintchone
🚀 SpaceX IPO is now available in the Fintch app - at a fixed price of $135 per share. Unlike most large IPOs, SpaceX didn't open with a price range. It named a single fixed price before book-building - an unusual move for a deal this size. The terms: • Price: $135 per share • Shares offered: 555.6M (100% primary - all proceeds go to the company) • Raise: ~$75B - the largest IPO on record • Valuation: ~$1.75T • Exchange: Nasdaq | Ticker: $SPCX • Trading begins June 12 What's inside the company: • Space - Falcon 9 launches and Starship, entering commercial service in H2 2026 • Connectivity - Starlink, ~5M subscribers, $11.4B revenue in 2025 (61% of total) and the only consistently profitable segment • AI - xAI (Grok) and the X platform, both folded in ahead of the offering The financials, as disclosed: • FY2025 revenue: $18.6B (+33% YoY) • FY2025 net loss: $4.94B • Q1 2026 revenue: $4.69B | net loss: $4.28B • xAI burned ~$2.5B in Q1 2026 Underwriters: Goldman Sachs, Morgan Stanley, BofA Securities, Citigroup, J.P. Morgan. On allocations: Demand is record-breaking - ~$14B has already flowed into funds holding SpaceX exposure. In hyped deals like this, most brokers fill only a small fraction of each request. Through Fintch, the average IPO allocation has historically been around 90% - so your chance of getting a meaningful position is materially higher here. 📲 Track the SpaceX deal in the Fintch app: https://t.co/CqMT1GPNnI
0
2
2
0
75
fintchone's profile image
Fintch Verified account @fintchone
⚡️ New IPO: INNIO Holding (#INIO) A new IPO is now available in the Fintch app. INNIO is an Austrian manufacturer of high-efficiency gas engines. Carved out of GE by Advent International in 2018 for $3.25B. Two historic brands: Jenbacher (80+ years) and Waukesha (100+ years). 44 GW installed base across 65,000+ engines in 110 countries. Bet on: data center order intake: $27M (2023) → $2.28B (2025) → $1.0B in Q1 2026 alone + $4.78B equipment backlog covering 18-24 months of revenue + signed agreement for a multi-gigawatt data center power plant + 10-15 year CSA service contracts on 65,000 installed engines + Jenbacher engines at up to 44% electrical efficiency - highest in the category + hydrogen-ready engine line in production. 📊 Key terms - Price range: $24-27 per share - Shares offered: 75,000,000 - Gross proceeds: $1.8-2.025B - Market cap: up to $20.25B at top of range - Exchange: Nasdaq Global Select Market | Ticker: INIO - Pricing: June 3, 2026 | Trading: June 4, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $2,636.8M (+22.1% YoY) - FY2025 Adj. EBITDA: $549.0M (20.8% margin, +19.4% YoY) - FY2025 net income: $141.8M (+54.1% YoY) - Q1 2026 revenue: $668.6M (+35.3% YoY) - Q1 2026 net loss: $7.2M (vs $35M income in Q1 2025) - IPO costs + FX - Valuation: ~34x Adj. EBITDA - premium to industrial peers (12-18x) - Structure: 100% secondary - all proceeds go to Advent/ADIA, zero to the company 🎯 Thesis Equipment (~60-65% of revenue) + Services (~35-40%) on 10-15 year CSA contracts. Services margins exceed Equipment margins - mix shifts favorably as installed base grows. AI data centers need reliable on-site power the grid cannot deliver at scale. INNIO is the European market leader in this category. Key risk: 100% secondary offering, no growth capital, Q1 2026 net loss. 🏛️ Co-lead bookrunners: Goldman Sachs, J.P. Morgan, Morgan Stanley. Bookrunners: BofA Securities, Barclays, Citigroup, Deutsche Bank, RBC Capital Markets, UBS. Co-managers: Crédit Agricole CIB, Erste Group, UniCredit, Academy Securities, Drexel Hamilton. 📅 Deadline: June 3, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. ⚡️ New IPO: INNIO Holding (#INIO) A new IPO is now available in the Fintch app. INNIO is an Austrian manufacturer of high-efficiency gas engines. Carved out of GE by Advent International in 2018 for $3.25B. Two historic brands: Jenbacher (80+ years) and Waukesha (100+ years). 44 GW installed base across 65,000+ engines in 110 countries. Bet on: data center order intake: $27M (2023) → $2.28B (2025) → $1.0B in Q1 2026 alone + $4.78B equipment backlog covering 18-24 months of revenue + signed agreement for a multi-gigawatt data center power plant + 10-15 year CSA service contracts on 65,000 installed engines + Jenbacher engines at up to 44% electrical efficiency - highest in the category + hydrogen-ready engine line in production. 📊 Key terms - Price range: $24-27 per share - Shares offered: 75,000,000 - Gross proceeds: $1.8-2.025B - Market cap: up to $20.25B at top of range - Exchange: Nasdaq Global Select Market | Ticker: INIO - Pricing: June 3, 2026 | Trading: June 4, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $2,636.8M (+22.1% YoY) - FY2025 Adj. EBITDA: $549.0M (20.8% margin, +19.4% YoY) - FY2025 net income: $141.8M (+54.1% YoY) - Q1 2026 revenue: $668.6M (+35.3% YoY) - Q1 2026 net loss: $7.2M (vs $35M income in Q1 2025) - IPO costs + FX - Valuation: ~34x Adj. EBITDA - premium to industrial peers (12-18x) - Structure: 100% secondary - all proceeds go to Advent/ADIA, zero to the company 🎯 Thesis Equipment (~60-65% of revenue) + Services (~35-40%) on 10-15 year CSA contracts. Services margins exceed Equipment margins - mix shifts favorably as installed base grows. AI data centers need reliable on-site power the grid cannot deliver at scale. INNIO is the European market leader in this category. Key risk: 100% secondary offering, no growth capital, Q1 2026 net loss. 🏛️ Co-lead bookrunners: Goldman Sachs, J.P. Morgan, Morgan Stanley. Bookrunners: BofA Securities, Barclays, Citigroup, Deutsche Bank, RBC Capital Markets, UBS. Co-managers: Crédit Agricole CIB, Erste Group, UniCredit, Academy Securities, Drexel Hamilton. 📅 Deadline: June 3, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
0
0
1
184
fintchone's profile image
Fintch Verified account @fintchone
⚛️ New IPO: Quantinuum (#QNT) A new IPO is now available in the Fintch app. Quantinuum is the world's only full-stack quantum computing company. Formed in 2021 from Honeywell Quantum Solutions and Cambridge Quantum Computing. Headquartered in Broomfield, Colorado and Cambridge, UK. The largest traditional (non-SPAC) quantum IPO in history. Bet on: Helios - 98-qubit trapped-ion processor with Quantum Volume exceeding 33.5M, surpassing the nearest competitor by 16,000x + only company with full hardware + software + applications stack (TKET, InQuanto, Nexus) + "Level 2 Resilient" quantum computer with Microsoft - 12 logical qubits at 2-in-1,000 error rate + $100M CHIPS Act grant (May 2026) + $677M cash + 500+ quantum patents + Defiance Quantum ETF +73% in the year prior to listing. 📊 Key terms - Price range: $45-50 per Class A share - Shares offered: ~21,050,000 Class A - Gross proceeds: $947M-$1.053B - Market cap: ~$12.7B at top of range - Exchange: Nasdaq | Ticker: QNT - Pricing: June 3, 2026 | Trading: June 4, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $30.9M (+34% YoY) | net loss: $192.6M (widening) - Q1 2026 revenue: $5.2M | net loss: $136.6M - Q1 2026 bookings: $1.3M (vs $1.9M in Q1 2025 - declining) - Valuation: 411x revenue - one of the most extreme multiples in this IPO wave - Last private round: Series B+ (Sep 2025) at $10B pre-money 🎯 Thesis Trapped-ion architecture delivers higher gate fidelity and lower noise than superconducting systems (IBM, Google). Quantum market: $1.3-2.5B today → $40-65B by 2030. QNT is the single most significant near-term catalyst for the entire quantum basket - a successful pricing re-rates the sector. Revenue is lumpy by design; this is a long-duration category bet. Most direct comparable: IonQ (IONQ, ~$6.5B). Key risk: widening losses, 411x multiple, no commercial quantum advantage demonstrated yet. 🏛️ Co-lead bookrunners: J.P. Morgan, Morgan Stanley. Active: Jefferies, Evercore ISI. Joint: BofA Securities, UBS Investment Bank. 📅 Deadline: June 3, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. ⚛️ New IPO: Quantinuum (#QNT) A new IPO is now available in the Fintch app. Quantinuum is the world's only full-stack quantum computing company. Formed in 2021 from Honeywell Quantum Solutions and Cambridge Quantum Computing. Headquartered in Broomfield, Colorado and Cambridge, UK. The largest traditional (non-SPAC) quantum IPO in history. Bet on: Helios - 98-qubit trapped-ion processor with Quantum Volume exceeding 33.5M, surpassing the nearest competitor by 16,000x + only company with full hardware + software + applications stack (TKET, InQuanto, Nexus) + "Level 2 Resilient" quantum computer with Microsoft - 12 logical qubits at 2-in-1,000 error rate + $100M CHIPS Act grant (May 2026) + $677M cash + 500+ quantum patents + Defiance Quantum ETF +73% in the year prior to listing. 📊 Key terms - Price range: $45-50 per Class A share - Shares offered: ~21,050,000 Class A - Gross proceeds: $947M-$1.053B - Market cap: ~$12.7B at top of range - Exchange: Nasdaq | Ticker: QNT - Pricing: June 3, 2026 | Trading: June 4, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $30.9M (+34% YoY) | net loss: $192.6M (widening) - Q1 2026 revenue: $5.2M | net loss: $136.6M - Q1 2026 bookings: $1.3M (vs $1.9M in Q1 2025 - declining) - Valuation: 411x revenue - one of the most extreme multiples in this IPO wave - Last private round: Series B+ (Sep 2025) at $10B pre-money 🎯 Thesis Trapped-ion architecture delivers higher gate fidelity and lower noise than superconducting systems (IBM, Google). Quantum market: $1.3-2.5B today → $40-65B by 2030. QNT is the single most significant near-term catalyst for the entire quantum basket - a successful pricing re-rates the sector. Revenue is lumpy by design; this is a long-duration category bet. Most direct comparable: IonQ (IONQ, ~$6.5B). Key risk: widening losses, 411x multiple, no commercial quantum advantage demonstrated yet. 🏛️ Co-lead bookrunners: J.P. Morgan, Morgan Stanley. Active: Jefferies, Evercore ISI. Joint: BofA Securities, UBS Investment Bank. 📅 Deadline: June 3, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
2
0
0
252
fintchone's profile image
Fintch Verified account @fintchone
✈️ New IPO: Applied Aerospace & Defense (#AADX) A new IPO is now available in the Fintch app. Applied Aerospace & Defense is a Huntsville, Alabama-based vertically integrated defense-industrial manufacturer. Formed in December 2025 through a merger of two historic subcontractors - Applied Aerospace (est. 1954) and PCX Aerosystems (est. 1900). Controlled by Greenbriar Equity Group. 11 manufacturing facilities, ~1.5M sq ft. 83% of revenue from US government contracts. Bet on: first public pure-play precision defense manufacturer embedded in F-35, B-21, and next-gen missile programs designed for 20-30 year lifecycles + SpaceX, Boeing, Northrop Grumman, ULA, Blue Origin as anchor Space & Launch customers + $1.06B contracted backlog (March 31, 2026) + $3.8B weighted pipeline + vertical integration from engineering through serial production to lifecycle sustainment creates structural switching costs + DoD FY2026 budget at $960B (+11.6% YoY, a record) + NATO commitments to 5% GDP defense spending as structural tailwind. 📊 Key terms - Price range: $18-21 per share - Shares offered: 32,500,000 - Gross proceeds: $585-682.5M - Market cap: ~$3.33B at midpoint ($19.50) - Exchange: NYSE - Ticker: AADX - Pricing: June 2, 2026 | Trading: June 3, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $498.8M (+24.8% YoY) - Pro forma FY2025 revenue (incl. CBI acquisition): $604.3M - Q1 2026 revenue: $134.4M (+21.0% YoY) - FY2025 Adj. EBITDA: $117.9M (+40.4% YoY); pro forma: $141.9M (23.5% margin) - Q1 2026 Adj. EBITDA margin: 19.8% - declining from 22.8% in Q1 2025 - Total debt: $1,017.8M | Debt/EBITDA: ~7.2x - Nearly all IPO proceeds ($589M of $634M net) directed to debt repayment - classic PE deleveraging, zero growth capital 🎯 Thesis Three segments: Space & Launch (~35-40% of revenue) - structural components and separation systems for rocket programs; Defense Aviation (~30-35%) - aircraft subsystems for F-35 and B-21 Raider; C5ISR & Precision Strike (~25-30%) - guidance systems and command infrastructure for Raytheon, L3Harris, GDLS. The moat is vertical integration - AAD reduces subcontractor count in prime contractor supply chains and becomes structurally embedded over multi-decade platform lifecycles. Platforms in production are designed for decades of operation, making sustainment revenue highly predictable. Most direct comparable: TransDigm Group (NYSE: TDG) - trades at ~25x EBITDA. AADX priced at ~26.5x EV/EBITDA at midpoint. Key difference: TransDigm runs 40%+ EBITDA margins vs AAD's 23.5%. Key risk: $1.0B debt post-IPO at 7.2x leverage. GAAP net loss widening in Q1 2026 ($15.1M vs $7.3M in Q1 2025). Declining EBITDA margins quarter-over-quarter. 🏛️ Co-lead bookrunners: Morgan Stanley, Jefferies. Joint bookrunners: BofA Securities, RBC Capital Markets, Guggenheim Securities, Baird, Stifel, Wolfe | Nomura Alliance. 📅 Deadline: June 2, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. ✈️ New IPO: Applied Aerospace & Defense (#AADX) A new IPO is now available in the Fintch app. Applied Aerospace & Defense is a Huntsville, Alabama-based vertically integrated defense-industrial manufacturer. Formed in December 2025 through a merger of two historic subcontractors - Applied Aerospace (est. 1954) and PCX Aerosystems (est. 1900). Controlled by Greenbriar Equity Group. 11 manufacturing facilities, ~1.5M sq ft. 83% of revenue from US government contracts. Bet on: first public pure-play precision defense manufacturer embedded in F-35, B-21, and next-gen missile programs designed for 20-30 year lifecycles + SpaceX, Boeing, Northrop Grumman, ULA, Blue Origin as anchor Space & Launch customers + $1.06B contracted backlog (March 31, 2026) + $3.8B weighted pipeline + vertical integration from engineering through serial production to lifecycle sustainment creates structural switching costs + DoD FY2026 budget at $960B (+11.6% YoY, a record) + NATO commitments to 5% GDP defense spending as structural tailwind. 📊 Key terms - Price range: $18-21 per share - Shares offered: 32,500,000 - Gross proceeds: $585-682.5M - Market cap: ~$3.33B at midpoint ($19.50) - Exchange: NYSE - Ticker: AADX - Pricing: June 2, 2026 | Trading: June 3, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $498.8M (+24.8% YoY) - Pro forma FY2025 revenue (incl. CBI acquisition): $604.3M - Q1 2026 revenue: $134.4M (+21.0% YoY) - FY2025 Adj. EBITDA: $117.9M (+40.4% YoY); pro forma: $141.9M (23.5% margin) - Q1 2026 Adj. EBITDA margin: 19.8% - declining from 22.8% in Q1 2025 - Total debt: $1,017.8M | Debt/EBITDA: ~7.2x - Nearly all IPO proceeds ($589M of $634M net) directed to debt repayment - classic PE deleveraging, zero growth capital 🎯 Thesis Three segments: Space & Launch (~35-40% of revenue) - structural components and separation systems for rocket programs; Defense Aviation (~30-35%) - aircraft subsystems for F-35 and B-21 Raider; C5ISR & Precision Strike (~25-30%) - guidance systems and command infrastructure for Raytheon, L3Harris, GDLS. The moat is vertical integration - AAD reduces subcontractor count in prime contractor supply chains and becomes structurally embedded over multi-decade platform lifecycles. Platforms in production are designed for decades of operation, making sustainment revenue highly predictable. Most direct comparable: TransDigm Group (NYSE: TDG) - trades at ~25x EBITDA. AADX priced at ~26.5x EV/EBITDA at midpoint. Key difference: TransDigm runs 40%+ EBITDA margins vs AAD's 23.5%. Key risk: $1.0B debt post-IPO at 7.2x leverage. GAAP net loss widening in Q1 2026 ($15.1M vs $7.3M in Q1 2025). Declining EBITDA margins quarter-over-quarter. 🏛️ Co-lead bookrunners: Morgan Stanley, Jefferies. Joint bookrunners: BofA Securities, RBC Capital Markets, Guggenheim Securities, Baird, Stifel, Wolfe | Nomura Alliance. 📅 Deadline: June 2, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
1
0
1
135
fintchone's profile image
Fintch Verified account @fintchone
🚀 SpaceX is building a second solar factory. The orbital data center play just got more concrete. On May 22, Starship V3 flew its first successful test - the heavy-lift vehicle SpaceX needs to put large payloads into orbit. This week, Bloomberg reported SpaceX is building a second 10 GW solar manufacturing plant near Austin, Texas. A first 10 GW facility already operates in the same county. 20 GW of annual solar capacity. For context, that's roughly what the entire US installs in a year. Musk laid it out in January: AI data centers are running out of power. Grid-connected land-based compute has a ceiling. The solution - move the data centers to orbit, power them with solar panels manufactured at scale. SpaceX's own projection: 100 terawatts of orbital compute capacity. Addressable market per Bloomberg: $28.5T. Why V3 matters here Orbital data centers require heavy, frequent launches. Falcon 9 can't do it at the required scale. V3 - with its engine-out tolerance proven this week - is the only vehicle in the pipeline that can. The vertical stack • Factory: solar panels at 20 GW/year • Vehicle: Starship V3 for orbital delivery • Infrastructure: orbital data centers • Revenue: compute-as-a-service from orbit All inside one company. All moving forward in the same week. The IPO is expected in June. Investors are pricing a rocket company. They may be underpricing an energy and compute infrastructure play. 👉 SpaceX IPO is now available in the Fintch app - you can participate today: Download
0
1
0
0
31
fintchone's profile image
Fintch Verified account @fintchone
🛢️ New IPO: EagleRock Land LLC (#EROK) A new IPO is now available in the Fintch app. EagleRock Land is a Houston-based land and royalty company controlling ~236,000 acres of surface rights in the core of the Permian Basin. EagleRock does not drill or produce - it monetizes surface access through royalties and fees for land, water, and infrastructure rights. Bet on: 236,000 acres of Permian surface rights + ~$45M annual contracted minimum royalties with zero incremental capex + one of the largest produced water handling systems in the Permian (~400,000 bbl/day) + EnCap and TCW as anchor PE investors + asset-light royalty model + LandBridge IPO precedent (shares tripled since 2024) + inflation-linked escalators on all key contracts. 📈 Key terms - Price range: $17-20 per Class A share - Shares offered: 17,300,000 Class A - Gross proceeds: $294-346M - Market cap: ~$2.6B at top of range - Exchanges: NYSE and NYSE Texas (dual listing) - Ticker: EROK - Pricing: May 13, 2026 | Trading: May 14, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $72.2M (+308% YoY from $17.7M in 2024) - Net loss FY2025: $73.1M - driven by non-cash DD&A, interest, and acquisition charges - Underlying operating cash flow likely materially positive (typical asset-light royalty profile) - Contracted minimum royalties: $40M/year (DE Flow WSMA, first 5 years) + $5M/year (Hydrosource Recycling, first 5 years) = ~$45M/year guaranteed baseline 🎯 Thesis Three revenue streams: resource sales (water, caliche), surface-use fees (rigs, pipelines, roads), and produced water royalties. Produced water volumes in the Permian historically exceed crude oil by 5-10x and keep growing - tightening regulation on disposal creates a moat for operators with diversified handling and recycling permits. Optionality beyond oil and gas: same acreage can be monetized for data centers, power generation, wind, solar, and crypto mining. Most direct precedent: LandBridge (NYSE: LB) - $283.6M IPO in mid-2024, shares tripled since. Long-term benchmark: Texas Pacific Land Corp (TPL) at $40B+ market cap. EROK is a "second chance" entry into this asset class. Key risk: meaningful portion of IPO proceeds goes to repaying the Predecessor Credit Facility and distributions to EnCap and TCW - typical PE-backed structure with partial sponsor exit. 🏛️ Co-lead bookrunners: Goldman Sachs, Barclays, J.P. Morgan. Additional: Piper Sandler, Raymond James, KeyBanc. Pickering Energy Partners as specialist Permian E&P co-manager. 📅 Deadline: May 12, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🛢️ New IPO: EagleRock Land LLC (#EROK) A new IPO is now available in the Fintch app. EagleRock Land is a Houston-based land and royalty company controlling ~236,000 acres of surface rights in the core of the Permian Basin. EagleRock does not drill or produce - it monetizes surface access through royalties and fees for land, water, and infrastructure rights. Bet on: 236,000 acres of Permian surface rights + ~$45M annual contracted minimum royalties with zero incremental capex + one of the largest produced water handling systems in the Permian (~400,000 bbl/day) + EnCap and TCW as anchor PE investors + asset-light royalty model + LandBridge IPO precedent (shares tripled since 2024) + inflation-linked escalators on all key contracts. 📈 Key terms - Price range: $17-20 per Class A share - Shares offered: 17,300,000 Class A - Gross proceeds: $294-346M - Market cap: ~$2.6B at top of range - Exchanges: NYSE and NYSE Texas (dual listing) - Ticker: EROK - Pricing: May 13, 2026 | Trading: May 14, 2026 - Lock-up: 93 days 💰 Financials - FY2025 revenue: $72.2M (+308% YoY from $17.7M in 2024) - Net loss FY2025: $73.1M - driven by non-cash DD&A, interest, and acquisition charges - Underlying operating cash flow likely materially positive (typical asset-light royalty profile) - Contracted minimum royalties: $40M/year (DE Flow WSMA, first 5 years) + $5M/year (Hydrosource Recycling, first 5 years) = ~$45M/year guaranteed baseline 🎯 Thesis Three revenue streams: resource sales (water, caliche), surface-use fees (rigs, pipelines, roads), and produced water royalties. Produced water volumes in the Permian historically exceed crude oil by 5-10x and keep growing - tightening regulation on disposal creates a moat for operators with diversified handling and recycling permits. Optionality beyond oil and gas: same acreage can be monetized for data centers, power generation, wind, solar, and crypto mining. Most direct precedent: LandBridge (NYSE: LB) - $283.6M IPO in mid-2024, shares tripled since. Long-term benchmark: Texas Pacific Land Corp (TPL) at $40B+ market cap. EROK is a "second chance" entry into this asset class. Key risk: meaningful portion of IPO proceeds goes to repaying the Predecessor Credit Facility and distributions to EnCap and TCW - typical PE-backed structure with partial sponsor exit. 🏛️ Co-lead bookrunners: Goldman Sachs, Barclays, J.P. Morgan. Additional: Piper Sandler, Raymond James, KeyBanc. Pickering Energy Partners as specialist Permian E&P co-manager. 📅 Deadline: May 12, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
1
0
0
106
fintchone's profile image
Fintch Verified account @fintchone
💼 New Private Equity opportunity: DeepSeek Our team would like to introduce a new Private Equity product available in the Fintch app – DeepSeek. DeepSeek has emerged as one of the most important new players in AI, challenging the assumption that frontier-level models require tens of billions in infrastructure spending. The company has demonstrated the ability to build highly capable models with significantly lower training and inference costs, creating a potential structural advantage as AI economics increasingly shift toward efficiency and scalable deployment. Beyond technology, DeepSeek is strategically positioned as an independent AI ecosystem outside the Western tech stack - a dynamic that may become increasingly important across Asia and emerging markets seeking technological sovereignty. 📊 Investment highlights Entry fee: 15% Success fee: 20% Current valuation: ~$20B Minimum investment: 100 USDT Structure Fintch acquires an LP interest in a Hong Kong Limited Partnership Fund targeting a direct allocation in DeepSeek equity. Investors receive proportional economic rights to the fund's position upon closing. (We're making a soft commit to this estimate valuation; if the final round estimate for us is higher, we'll refund the money) 🚀 Growth potential DeepSeek's approach to efficient model development positions the company at the center of Asia's emerging AI infrastructure - a market expanding rapidly as demand for cost-effective, sovereignty-aligned alternatives grows globally. 📒 Deal closes: May 11, 2026 📲 Private Equity opportunities are available in the Fintch app https://t.co/CqMT1GPNnI
fintchone's tweet photo. 💼 New Private Equity opportunity: DeepSeek Our team would like to introduce a new Private Equity product available in the Fintch app – DeepSeek. DeepSeek has emerged as one of the most important new players in AI, challenging the assumption that frontier-level models require tens of billions in infrastructure spending. The company has demonstrated the ability to build highly capable models with significantly lower training and inference costs, creating a potential structural advantage as AI economics increasingly shift toward efficiency and scalable deployment. Beyond technology, DeepSeek is strategically positioned as an independent AI ecosystem outside the Western tech stack - a dynamic that may become increasingly important across Asia and emerging markets seeking technological sovereignty. 📊 Investment highlights Entry fee: 15% Success fee: 20% Current valuation: ~$20B Minimum investment: 100 USDT Structure Fintch acquires an LP interest in a Hong Kong Limited Partnership Fund targeting a direct allocation in DeepSeek equity. Investors receive proportional economic rights to the fund's position upon closing. (We're making a soft commit to this estimate valuation; if the final round estimate for us is higher, we'll refund the money) 🚀 Growth potential DeepSeek's approach to efficient model development positions the company at the center of Asia's emerging AI infrastructure - a market expanding rapidly as demand for cost-effective, sovereignty-aligned alternatives grows globally. 📒 Deal closes: May 11, 2026 📲 Private Equity opportunities are available in the Fintch app https://t.co/CqMT1GPNnI
0
1
0
0
48
fintchone's profile image
Fintch Verified account @fintchone
🧬 New IPO: Odyssey Therapeutics (#ODTX) A new IPO is now available in the Fintch app. Odyssey Therapeutics is a clinical-stage biopharmaceutical company founded in 2021 in Boston, Massachusetts. The company develops precision small molecules targeting upstream signaling pathways in the innate immune system for autoimmune and inflammatory diseases. Second IPO attempt - first withdrawn in 2025. Bet on: first-in-class RIPK2 inhibitor (OD-001) in Phase 2a/2b for ulcerative colitis + SLC15A4 inhibitor (OD-002) for SLE/lupus + no approved competitors in either target + AI/ML discovery platform + $726.5M total raised + CEO Gary Glick's serial biotech success. 📈 Key terms - Price range: $16-18 per share - Market cap: ~$809.9M at top of range - Capital raised: ~$211-238M - Exchange: Nasdaq - Ticker: ODTX - Lock-up: 93 days 💰 Financials - FY2025 revenue: $3M (pre-revenue clinical stage) - Cash at April 2026: $175.7M - Total raised: ~$726.5M - Series D (Sept 2025): $213M oversubscribed 🎯 Thesis OD-001: first-in-class RIPK2 inhibitor for UC - Phase 2 monotherapy + Phase 2b combination with Takeda's Entyvio underway. OD-002: targets SLC15A4 (TLR pathway) for SLE/lupus - no approved SLC15A4 inhibitors exist; SLE market exceeds $8B. Broader TLR7/8 inhibitor pipeline. OrbiMed anchor investor since inception. 🏛️ Co-lead bookrunners J.P. Morgan, TD Cowen, Cantor Fitzgerald, Wedbush PacGrow, Oppenheimer 📅 Order submission deadline: May 7, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🧬 New IPO: Odyssey Therapeutics (#ODTX) A new IPO is now available in the Fintch app. Odyssey Therapeutics is a clinical-stage biopharmaceutical company founded in 2021 in Boston, Massachusetts. The company develops precision small molecules targeting upstream signaling pathways in the innate immune system for autoimmune and inflammatory diseases. Second IPO attempt - first withdrawn in 2025. Bet on: first-in-class RIPK2 inhibitor (OD-001) in Phase 2a/2b for ulcerative colitis + SLC15A4 inhibitor (OD-002) for SLE/lupus + no approved competitors in either target + AI/ML discovery platform + $726.5M total raised + CEO Gary Glick's serial biotech success. 📈 Key terms - Price range: $16-18 per share - Market cap: ~$809.9M at top of range - Capital raised: ~$211-238M - Exchange: Nasdaq - Ticker: ODTX - Lock-up: 93 days 💰 Financials - FY2025 revenue: $3M (pre-revenue clinical stage) - Cash at April 2026: $175.7M - Total raised: ~$726.5M - Series D (Sept 2025): $213M oversubscribed 🎯 Thesis OD-001: first-in-class RIPK2 inhibitor for UC - Phase 2 monotherapy + Phase 2b combination with Takeda's Entyvio underway. OD-002: targets SLC15A4 (TLR pathway) for SLE/lupus - no approved SLC15A4 inhibitors exist; SLE market exceeds $8B. Broader TLR7/8 inhibitor pipeline. OrbiMed anchor investor since inception. 🏛️ Co-lead bookrunners J.P. Morgan, TD Cowen, Cantor Fitzgerald, Wedbush PacGrow, Oppenheimer 📅 Order submission deadline: May 7, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
2
0
0
148
fintchone's profile image
Fintch Verified account @fintchone
🧠 New IPO: Mobia Medical (#MOBI) A new IPO is now available in the Fintch app. Mobia Medical (formerly MicroTransponder) develops the Vivistim® Paired VNS™ System - the only FDA-approved implantable for upper extremity motor impairment in post-stroke survivors. Founded 2007, Austin, Texas. Bet on: only approved neurorecovery solution for chronic stroke + $32M FY2025 revenue + 81% gross margin + CMS Medicare reimbursement approved (Nov 2025) + 1,000+ systems implanted + $30B+ addressable market. 📈 Key terms - Price range: $14-16 per share - Market cap: ~$529M at top of range - Capital raised: ~$140-160M - Exchange: Nasdaq - Ticker: MOBI - Lock-up: 93 days 💰 Financials - FY2025 revenue: $32M (commercial-stage) - Gross margin: 81% - Total raised: ~$229.5M across 6 rounds - Series F (March 2025): $65M 🎯 Thesis Addressable market: ~4M new chronic stroke cases annually in US, ~1M eligible for therapy. Vivistim targets the regulatory "white space" - post-acute stroke (6+ months) where no prior FDA approval existed. Medicare reimbursement approval (Nov 2025) is the near-term catalyst unlocking adoption at scale. 🏛️ Co-lead bookrunners BofA Securities, J.P. Morgan, Goldman Sachs 📅 Order submission deadline: May 7, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🧠 New IPO: Mobia Medical (#MOBI) A new IPO is now available in the Fintch app. Mobia Medical (formerly MicroTransponder) develops the Vivistim® Paired VNS™ System - the only FDA-approved implantable for upper extremity motor impairment in post-stroke survivors. Founded 2007, Austin, Texas. Bet on: only approved neurorecovery solution for chronic stroke + $32M FY2025 revenue + 81% gross margin + CMS Medicare reimbursement approved (Nov 2025) + 1,000+ systems implanted + $30B+ addressable market. 📈 Key terms - Price range: $14-16 per share - Market cap: ~$529M at top of range - Capital raised: ~$140-160M - Exchange: Nasdaq - Ticker: MOBI - Lock-up: 93 days 💰 Financials - FY2025 revenue: $32M (commercial-stage) - Gross margin: 81% - Total raised: ~$229.5M across 6 rounds - Series F (March 2025): $65M 🎯 Thesis Addressable market: ~4M new chronic stroke cases annually in US, ~1M eligible for therapy. Vivistim targets the regulatory "white space" - post-acute stroke (6+ months) where no prior FDA approval existed. Medicare reimbursement approval (Nov 2025) is the near-term catalyst unlocking adoption at scale. 🏛️ Co-lead bookrunners BofA Securities, J.P. Morgan, Goldman Sachs 📅 Order submission deadline: May 7, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
2
0
0
107
fintchone's profile image
Fintch Verified account @fintchone
🚑 New IPO: GMR Solutions (#GMRS) A new IPO is now available in the Fintch app. GMR Solutions (trading as Global Medical Response) is the largest US provider of emergency medical services (EMS), formed in 2018 through the merger of Air Medical Group Holdings and American Medical Response - both KKR portfolio companies. Headquartered in Lewisville, Texas. Largest healthcare-services IPO of Spring 2026 by revenue. Bet on: only national fully-integrated air and ground EMS provider + $5.74B FY2025 revenue + $1.19B Adjusted EBITDA (+8% YoY) + 10% of all US 911 calls handled + sole EMS partner under FEMA's National Ambulance Contract + Nurse Navigation program covering 19M+ insured lives. 📈 Key terms - Price range: $22-25 per share - Market cap: ~$5.0B at top of range - Capital raised: ~$702-798M - Exchange: NYSE - Ticker: GMRS - Lock-up: 93 days 💰 Financials - FY2025 revenue: $5.74B (-4% YoY from $5.98B in 2024) - Adjusted EBITDA: $1.19B (~20.7% margin, +8% YoY) - Net income FY2025: $206.2M (vs. $20.4M in 2024 - ~10x growth) - Patient encounters: ~5.5M annually, 4.18M ambulance transports - Revenue mix: 59% commercial insurers, 24% Medicare, 8% Medicaid - Total debt: $5.05B (key risk) - refinanced in 2025, primary tranche matures 2032 - Available liquidity: $695.1M 🎯 Thesis GMR operates 7,400 ground vehicles, 400 rotor-wing and 115 fixed-wing aircraft across 45 states - covering communities where 60%+ of the US population lives. Demand is structurally non-discretionary: it grows with population age and healthcare system fragility. Air ambulance market projected at $21.2B by 2030. Key innovation: Nurse Navigation program - specially trained nurses intercept lower-acuity 911 calls and redirect patients to telehealth or urgent care, reducing unnecessary ED visits. Covered 19M+ insured lives by year-end 2025. Competitors (Air Methods, PHI Air Medical, Falck) are all private and regionally limited. GMR is the only operator at national scale with fully integrated air and ground coverage. Key risk: $5.05B debt load. A significant portion of IPO proceeds addresses balance sheet restructuring, not operational growth. 🏛️ Co-lead bookrunners: J.P. Morgan, KKR Capital Markets, BofA Securities 📅 Order submission deadline: May 12, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🚑 New IPO: GMR Solutions (#GMRS) A new IPO is now available in the Fintch app. GMR Solutions (trading as Global Medical Response) is the largest US provider of emergency medical services (EMS), formed in 2018 through the merger of Air Medical Group Holdings and American Medical Response - both KKR portfolio companies. Headquartered in Lewisville, Texas. Largest healthcare-services IPO of Spring 2026 by revenue. Bet on: only national fully-integrated air and ground EMS provider + $5.74B FY2025 revenue + $1.19B Adjusted EBITDA (+8% YoY) + 10% of all US 911 calls handled + sole EMS partner under FEMA's National Ambulance Contract + Nurse Navigation program covering 19M+ insured lives. 📈 Key terms - Price range: $22-25 per share - Market cap: ~$5.0B at top of range - Capital raised: ~$702-798M - Exchange: NYSE - Ticker: GMRS - Lock-up: 93 days 💰 Financials - FY2025 revenue: $5.74B (-4% YoY from $5.98B in 2024) - Adjusted EBITDA: $1.19B (~20.7% margin, +8% YoY) - Net income FY2025: $206.2M (vs. $20.4M in 2024 - ~10x growth) - Patient encounters: ~5.5M annually, 4.18M ambulance transports - Revenue mix: 59% commercial insurers, 24% Medicare, 8% Medicaid - Total debt: $5.05B (key risk) - refinanced in 2025, primary tranche matures 2032 - Available liquidity: $695.1M 🎯 Thesis GMR operates 7,400 ground vehicles, 400 rotor-wing and 115 fixed-wing aircraft across 45 states - covering communities where 60%+ of the US population lives. Demand is structurally non-discretionary: it grows with population age and healthcare system fragility. Air ambulance market projected at $21.2B by 2030. Key innovation: Nurse Navigation program - specially trained nurses intercept lower-acuity 911 calls and redirect patients to telehealth or urgent care, reducing unnecessary ED visits. Covered 19M+ insured lives by year-end 2025. Competitors (Air Methods, PHI Air Medical, Falck) are all private and regionally limited. GMR is the only operator at national scale with fully integrated air and ground coverage. Key risk: $5.05B debt load. A significant portion of IPO proceeds addresses balance sheet restructuring, not operational growth. 🏛️ Co-lead bookrunners: J.P. Morgan, KKR Capital Markets, BofA Securities 📅 Order submission deadline: May 12, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
2
0
0
103
fintchone's profile image
Fintch Verified account @fintchone
🤖 New IPO: Cerebras Systems Inc (#CBRS) A new IPO is now available in the Fintch app. Cerebras Systems is an American AI semiconductor company founded in 2016 in Sunnyvale, California. The company designs AI computing systems based on the Wafer-Scale Engine (WSE) - a chip that is physically an entire 300mm silicon wafer - targeting the low-latency AI inference segment. Bet on: only wafer-scale AI chip company with no direct architectural competitor + $510M FY2025 revenue (+76% YoY) + $87.9M GAAP net income (first profitable year) + $24.6B backlog + AWS Bedrock integration (March 2026) + 20-25x faster token generation vs Nvidia H100. 📈 Key terms - Price range: $115-125 per share - Market cap: ~$26.6B at top of range - Capital raised: ~$3.22-3.50B - Exchange: Nasdaq Global Select Market - Ticker: CBRS - Lock-up: 93 days 💰 Financials - FY2025 revenue: $510M (+76% YoY); three-year growth ~20x - Hardware: $358M; Cloud services: $152M - Gross margin: ~39% (up from 12% in FY2022) - GAAP net income: $87.9M - first profitable year after $485M net loss in FY2024 - Backlog: $24.6B as of Dec 31, 2025 - Customer concentration: MBZUAI + G42 (UAE) - 86% of total revenue - Series H (Feb 2026, $1B at $23B valuation): Tiger Global, AMD, Fidelity, Benchmark, Coatue, Altimeter 🎯 Thesis WSE-3: 46,225 sq mm, TSMC 5nm, 4 trillion transistors, 900,000 AI cores, 44 GB on-chip SRAM. Eliminates memory bus latency - the primary GPU inference bottleneck - delivering 20-25x faster token generation vs Nvidia H100. No direct architectural competitor in wafer-scale AI computing. AWS Bedrock integration shifts distribution to cloud-native channel. OpenAI provided a $1B loan at 6% for data center infrastructure. Key risk: UAE customer concentration (86%) - MBZUAI and G42 restructured post-CFIUS review, clearance received March 2025. Second IPO attempt - first withdrawn in 2024 due to CFIUS scrutiny. 🏛️ Co-lead bookrunners: Morgan Stanley, Citigroup, Barclays, UBS Investment Bank 📅 Order submission deadline: May 13, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🤖 New IPO: Cerebras Systems Inc (#CBRS) A new IPO is now available in the Fintch app. Cerebras Systems is an American AI semiconductor company founded in 2016 in Sunnyvale, California. The company designs AI computing systems based on the Wafer-Scale Engine (WSE) - a chip that is physically an entire 300mm silicon wafer - targeting the low-latency AI inference segment. Bet on: only wafer-scale AI chip company with no direct architectural competitor + $510M FY2025 revenue (+76% YoY) + $87.9M GAAP net income (first profitable year) + $24.6B backlog + AWS Bedrock integration (March 2026) + 20-25x faster token generation vs Nvidia H100. 📈 Key terms - Price range: $115-125 per share - Market cap: ~$26.6B at top of range - Capital raised: ~$3.22-3.50B - Exchange: Nasdaq Global Select Market - Ticker: CBRS - Lock-up: 93 days 💰 Financials - FY2025 revenue: $510M (+76% YoY); three-year growth ~20x - Hardware: $358M; Cloud services: $152M - Gross margin: ~39% (up from 12% in FY2022) - GAAP net income: $87.9M - first profitable year after $485M net loss in FY2024 - Backlog: $24.6B as of Dec 31, 2025 - Customer concentration: MBZUAI + G42 (UAE) - 86% of total revenue - Series H (Feb 2026, $1B at $23B valuation): Tiger Global, AMD, Fidelity, Benchmark, Coatue, Altimeter 🎯 Thesis WSE-3: 46,225 sq mm, TSMC 5nm, 4 trillion transistors, 900,000 AI cores, 44 GB on-chip SRAM. Eliminates memory bus latency - the primary GPU inference bottleneck - delivering 20-25x faster token generation vs Nvidia H100. No direct architectural competitor in wafer-scale AI computing. AWS Bedrock integration shifts distribution to cloud-native channel. OpenAI provided a $1B loan at 6% for data center infrastructure. Key risk: UAE customer concentration (86%) - MBZUAI and G42 restructured post-CFIUS review, clearance received March 2025. Second IPO attempt - first withdrawn in 2024 due to CFIUS scrutiny. 🏛️ Co-lead bookrunners: Morgan Stanley, Citigroup, Barclays, UBS Investment Bank 📅 Order submission deadline: May 13, 2026 (inclusive) 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
2
0
0
294
fintchone's profile image
Fintch Verified account @fintchone
🥤 New IPO: Suja Life Inc (#SUJA) A new IPO is now available in the Fintch app. Suja Life Inc is an American functional beverage company founded in 2012 in Oceanside, California. The company is the national leader in organic cold-pressed juices and wellness shots, operating three brands: Suja Organic (cold-pressed juices and shots), Vive Organic (immunity and energy shots), and Slice (functional soda). Since 2021, Suja has been owned by Paine Schwartz Partners, a private equity firm focused exclusively on sustainable food chain investing. Bet on: 47% market share in US cold-pressed juice + $219M FY2025 sales (+26% YoY) + $40.5M EBITDA FY2025 + 37,000+ retail locations + proprietary HPP technology (barrier to entry) + Coca-Cola as historical investor + Q1 2026 showing sharp operating leverage improvement + expanding wellness category tailwind. 📈 Key terms - Price range: $21–24 per share - Market cap: ~$1B at top of range - Capital raised: ~$213.3M - Shares offered: 8,888,889 - Exchange: Nasdaq Global Select Market - Ticker: SUJA - Lock-up: 93 days 💰 Financials - FY2025 net sales: $326.6M (up 26.1% YoY) - Adjusted EBITDA FY2025: $40.5M (~12.4% margin) - Net loss FY2025: $23.3M (vs. $20.8M loss in FY2024) - losses driven by debt service, acquisition charges - Q1 2026 preliminary: $103.8–107.1M sales (~19–22% growth), net income $7–8.8M (vs. $88k loss in Q1 2025) - Distribution: 37,000+ US retail locations, 380,000+ points of distribution - At Paine Schwartz acquisition (2021): revenue ~$200M, now grown 63% in five years 🎯 Thesis Suja dominates the US cold-pressed juice market (47% share) with three distinct brands covering separate segments: Suja Organic (~78% of revenue, #1 organic cold-pressed juice), Vive Organic (wellness shots, 42% wellness category share), Slice (functional soda relaunch 2024, fastest-growing component). Proprietary HPP (High Pressure Processing) technology —destroys bacteria without heat, preserves nutrients and taste — creates structural moat; building large HPP campus requires capital and years of expertise. Macro tailwind: consumer shift away from traditional carbonated soft drinks toward better-for-you alternatives, growing immunity and gut health categories. Q1 2026 results signal inflection: net income turned sharply positive ($7–8.8M vs. $88k loss Q1 2025), signaling operating leverage beginning to materialize as growth scales. Competitive landscape: Suja faces direct competition from Evolution Fresh (Starbucks), Pressed Juicery, private labels, and strategic competitors (Coca-Cola acquired Poppi for $1.95B, launched Honest Tea and Smartwater lines, owns stakes in Nestlé functional brands). However, Coca-Cola's historical investment in Suja signals confidence and could be M&A catalyst. Bookrunner syndicate (Goldman, Jefferies, William Blair) reflects mid-market consumer positioning. Up-C structure post-IPO: Paine Schwartz retains control via LP units in operating partnership. Pipeline: 3 brands, 14M buyers (NielOmni shopper data), continued retail expansion, margin accretion as scale improves. 🏛️ Lead underwriters: Goldman Sachs & Co. LLC, Jefferies, William Blair 📅 Order submission deadline: May 7, 2026 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🥤 New IPO: Suja Life Inc (#SUJA) A new IPO is now available in the Fintch app. Suja Life Inc is an American functional beverage company founded in 2012 in Oceanside, California. The company is the national leader in organic cold-pressed juices and wellness shots, operating three brands: Suja Organic (cold-pressed juices and shots), Vive Organic (immunity and energy shots), and Slice (functional soda). Since 2021, Suja has been owned by Paine Schwartz Partners, a private equity firm focused exclusively on sustainable food chain investing. Bet on: 47% market share in US cold-pressed juice + $219M FY2025 sales (+26% YoY) + $40.5M EBITDA FY2025 + 37,000+ retail locations + proprietary HPP technology (barrier to entry) + Coca-Cola as historical investor + Q1 2026 showing sharp operating leverage improvement + expanding wellness category tailwind. 📈 Key terms - Price range: $21–24 per share - Market cap: ~$1B at top of range - Capital raised: ~$213.3M - Shares offered: 8,888,889 - Exchange: Nasdaq Global Select Market - Ticker: SUJA - Lock-up: 93 days 💰 Financials - FY2025 net sales: $326.6M (up 26.1% YoY) - Adjusted EBITDA FY2025: $40.5M (~12.4% margin) - Net loss FY2025: $23.3M (vs. $20.8M loss in FY2024) - losses driven by debt service, acquisition charges - Q1 2026 preliminary: $103.8–107.1M sales (~19–22% growth), net income $7–8.8M (vs. $88k loss in Q1 2025) - Distribution: 37,000+ US retail locations, 380,000+ points of distribution - At Paine Schwartz acquisition (2021): revenue ~$200M, now grown 63% in five years 🎯 Thesis Suja dominates the US cold-pressed juice market (47% share) with three distinct brands covering separate segments: Suja Organic (~78% of revenue, #1 organic cold-pressed juice), Vive Organic (wellness shots, 42% wellness category share), Slice (functional soda relaunch 2024, fastest-growing component). Proprietary HPP (High Pressure Processing) technology —destroys bacteria without heat, preserves nutrients and taste — creates structural moat; building large HPP campus requires capital and years of expertise. Macro tailwind: consumer shift away from traditional carbonated soft drinks toward better-for-you alternatives, growing immunity and gut health categories. Q1 2026 results signal inflection: net income turned sharply positive ($7–8.8M vs. $88k loss Q1 2025), signaling operating leverage beginning to materialize as growth scales. Competitive landscape: Suja faces direct competition from Evolution Fresh (Starbucks), Pressed Juicery, private labels, and strategic competitors (Coca-Cola acquired Poppi for $1.95B, launched Honest Tea and Smartwater lines, owns stakes in Nestlé functional brands). However, Coca-Cola's historical investment in Suja signals confidence and could be M&A catalyst. Bookrunner syndicate (Goldman, Jefferies, William Blair) reflects mid-market consumer positioning. Up-C structure post-IPO: Paine Schwartz retains control via LP units in operating partnership. Pipeline: 3 brands, 14M buyers (NielOmni shopper data), continued retail expansion, margin accretion as scale improves. 🏛️ Lead underwriters: Goldman Sachs & Co. LLC, Jefferies, William Blair 📅 Order submission deadline: May 7, 2026 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
1
0
0
76
fintchone's profile image
Fintch Verified account @fintchone
🛰️ New IPO: HawkEye 360 (#HAWK) A new IPO is now available in the Fintch app. HawkEye 360 Inc is a U.S.-based commercial signals intelligence (SIGINT) company founded in 2015 and headquartered in Herndon, Virginia. The company operates the world's largest commercial RF satellite constellation (30+ satellites in orbit as of January 2026, expanding to 80+ eventually). HawkEye 360 delivers radio frequency intelligence products—Custody ID (maritime vessel tracking), GNSS Interference Detection (GPS jamming/spoofing), Electronic Order of Battle (adversary radar mapping), and Communications Mapping—to defense, intelligence, and government customers worldwide. Bet on: only commercial RF SIGINT company at scale + $24.8M EBITDA in FY2025 (breakeven reached) + $117.7M revenue (+74% YoY, FY2025) + constellation expansion licensed by FCC to 80 satellites + $98.8M Navy contract extension (Indo-Pacific Partnership) + NATO and European Ministry of Defense contracts + operational validation in Ukraine + $24 billion TAM expanding to $34 billion by 2030. 📈 Key terms - Price range: $24–26 per share - Market cap: ~$2.4B at top of range - Capital raised: ~$384–416M - Shares offered: 16M - Exchange: New York Stock Exchange (NYSE) - Ticker: HAWK - Lock-up: 93 days 💰 Financials - FY2025 revenue: $117.7M (up 74% YoY from $67.6M in FY2024) - Three-year CAGR (2022-2025): ~57% - Adjusted EBITDA FY2025: $24.8M (~21% margin) - first breakeven year following net loss of $31.2M in FY2024 - Backlog: $302.7M (as of Dec 31, 2025) - Revenue mix: US government 61%, Japan 16%, international 23% - Total capital raised: ~$560–584M across 14+ rounds since 2015 - Key institutional investors: Raytheon (Series A), Lockheed Martin (D-1), NightDragon (E), Center15 Capital, Insight Partners, Paladin, SVB, Hercules, Pinegrove, Ghisallo - Series E (Dec 2025): $150M equity + debt for ISA acquisition; additional $23M raised March 2026 🎯 Thesis HawkEye 360 is the only commercial RF SIGINT company operating a large satellite constellation (30+) at profitability. Traditional defense contractors (Northrop, Raytheon, L3Harris) run classified systems with restricted data. HawkEye made RF data "shareable" - selling intelligence products (Custody ID, GNSS Interference Detection, ELINT mapping) to military and allies. December 2025 ISA acquisition added ELINT algorithms and classified DoD contractor capability. Key contracts: NRO RF data (extended Dec 2025), US Navy Indo-Pacific ($98.8M), US Space Force JCO, NGA, European Ministry of Defense ($75M five-year), undisclosed international partner ($100M+). Macro: NATO 5% defense spending commitment, US DoD FY2026 ~$960B, operational validation in Ukraine = strongest commercial reference possible. Pipeline: 30+ satellites live, FCC licensed for 80 total. ISA integration unlocks ELINT + air defense radar mapping in 2026-2027. 🏛️ Lead underwriters: Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, BofA Securities, RBC Capital Markets. Co-managers: Baird, Raymond James, William Blair, Drexel Hamilton 📅 Order submission deadline: May 7, 2026 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🛰️ New IPO: HawkEye 360 (#HAWK) A new IPO is now available in the Fintch app. HawkEye 360 Inc is a U.S.-based commercial signals intelligence (SIGINT) company founded in 2015 and headquartered in Herndon, Virginia. The company operates the world's largest commercial RF satellite constellation (30+ satellites in orbit as of January 2026, expanding to 80+ eventually). HawkEye 360 delivers radio frequency intelligence products—Custody ID (maritime vessel tracking), GNSS Interference Detection (GPS jamming/spoofing), Electronic Order of Battle (adversary radar mapping), and Communications Mapping—to defense, intelligence, and government customers worldwide. Bet on: only commercial RF SIGINT company at scale + $24.8M EBITDA in FY2025 (breakeven reached) + $117.7M revenue (+74% YoY, FY2025) + constellation expansion licensed by FCC to 80 satellites + $98.8M Navy contract extension (Indo-Pacific Partnership) + NATO and European Ministry of Defense contracts + operational validation in Ukraine + $24 billion TAM expanding to $34 billion by 2030. 📈 Key terms - Price range: $24–26 per share - Market cap: ~$2.4B at top of range - Capital raised: ~$384–416M - Shares offered: 16M - Exchange: New York Stock Exchange (NYSE) - Ticker: HAWK - Lock-up: 93 days 💰 Financials - FY2025 revenue: $117.7M (up 74% YoY from $67.6M in FY2024) - Three-year CAGR (2022-2025): ~57% - Adjusted EBITDA FY2025: $24.8M (~21% margin) - first breakeven year following net loss of $31.2M in FY2024 - Backlog: $302.7M (as of Dec 31, 2025) - Revenue mix: US government 61%, Japan 16%, international 23% - Total capital raised: ~$560–584M across 14+ rounds since 2015 - Key institutional investors: Raytheon (Series A), Lockheed Martin (D-1), NightDragon (E), Center15 Capital, Insight Partners, Paladin, SVB, Hercules, Pinegrove, Ghisallo - Series E (Dec 2025): $150M equity + debt for ISA acquisition; additional $23M raised March 2026 🎯 Thesis HawkEye 360 is the only commercial RF SIGINT company operating a large satellite constellation (30+) at profitability. Traditional defense contractors (Northrop, Raytheon, L3Harris) run classified systems with restricted data. HawkEye made RF data "shareable" - selling intelligence products (Custody ID, GNSS Interference Detection, ELINT mapping) to military and allies. December 2025 ISA acquisition added ELINT algorithms and classified DoD contractor capability. Key contracts: NRO RF data (extended Dec 2025), US Navy Indo-Pacific ($98.8M), US Space Force JCO, NGA, European Ministry of Defense ($75M five-year), undisclosed international partner ($100M+). Macro: NATO 5% defense spending commitment, US DoD FY2026 ~$960B, operational validation in Ukraine = strongest commercial reference possible. Pipeline: 30+ satellites live, FCC licensed for 80 total. ISA integration unlocks ELINT + air defense radar mapping in 2026-2027. 🏛️ Lead underwriters: Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, BofA Securities, RBC Capital Markets. Co-managers: Baird, Raymond James, William Blair, Drexel Hamilton 📅 Order submission deadline: May 7, 2026 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
2
0
0
76
fintchone's profile image
Fintch Verified account @fintchone
💊 New IPO: Hemab Therapeutics (#COAG) A new IPO is now available in the Fintch app. Hemab Therapeutics Holdings Inc is a U.S.-based clinical-stage biopharmaceutical company focused on rare bleeding and coagulation disorders. The company develops antibody-based prophylactic therapies targeting Glanzmann thrombastenia (GT), Factor VII deficiency (FVIID), and Von Willebrand Disease (VWD) - three rare indications where no approved subcutaneous prophylactic therapies currently exist. Bet on: first-in-class antibody platform + orphan drug economics ($300K–$1M per patient annually) + 130K addressable patients + FDA Fast Track + Breakthrough Therapy designation + strategic partnerships with Novo Nordisk and Genmab. 📈 Key terms – Price range: $16–18 per share – Market cap: ~$705.7M at top of range – Capital raised: ~$200–212M – Exchange: Nasdaq Global Select Market – Ticker: COAG – Lock-up: 93 days 💰 Financials – Revenue: $0 (clinical-stage, pre-commercial) – Cash on hand: $185.5M (end of 2025) – Total capital raised since inception: ~$346M – All proceeds directed to R&D and clinical development 🎯 Thesis No approved subcutaneous prophylactic exists for GT and FVIID - Sutacimig (HMB-001), if approved, would define an entirely new treatment category and be first-in-class. VWD has weak prophylactic options, creating meaningful unmet need. Orphan drug pricing model ($300K–$1M annually) + limited competition + small but concentrated patient population (~130K total addressable) = high margin potential despite narrow indication. Exceptional regulatory tailwind: FDA Fast Track, Breakthrough Therapy, Orphan Drug + EMA Orphan + UK ILAP signals FDA confidence. CEO Benny Sørensen brings 25 years in coagulation medicine from Codiak, Alnylam, Baxter. Goldman Sachs as lead bookrunner (unusual for small biotech) signals institutional-grade conviction and quality. Pipeline: Sutacimig in Phase 3 for GT, Phase 2 for FVIID (data late 2026/early 2027). HMB-002 targeting VWD in Phase 1/2. HMB-003 preclinical, clinic initiation planned H2 2026. 🏛️ Lead underwriters: Goldman Sachs & Co., Jefferies, Evercore ISI, Wedbush PacGrow 📅 Order submission deadline: April 30, 2026 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
fintchone's tweet photo. 💊 New IPO: Hemab Therapeutics (#COAG) A new IPO is now available in the Fintch app. Hemab Therapeutics Holdings Inc is a U.S.-based clinical-stage biopharmaceutical company focused on rare bleeding and coagulation disorders. The company develops antibody-based prophylactic therapies targeting Glanzmann thrombastenia (GT), Factor VII deficiency (FVIID), and Von Willebrand Disease (VWD) - three rare indications where no approved subcutaneous prophylactic therapies currently exist. Bet on: first-in-class antibody platform + orphan drug economics ($300K–$1M per patient annually) + 130K addressable patients + FDA Fast Track + Breakthrough Therapy designation + strategic partnerships with Novo Nordisk and Genmab. 📈 Key terms – Price range: $16–18 per share – Market cap: ~$705.7M at top of range – Capital raised: ~$200–212M – Exchange: Nasdaq Global Select Market – Ticker: COAG – Lock-up: 93 days 💰 Financials – Revenue: $0 (clinical-stage, pre-commercial) – Cash on hand: $185.5M (end of 2025) – Total capital raised since inception: ~$346M – All proceeds directed to R&D and clinical development 🎯 Thesis No approved subcutaneous prophylactic exists for GT and FVIID - Sutacimig (HMB-001), if approved, would define an entirely new treatment category and be first-in-class. VWD has weak prophylactic options, creating meaningful unmet need. Orphan drug pricing model ($300K–$1M annually) + limited competition + small but concentrated patient population (~130K total addressable) = high margin potential despite narrow indication. Exceptional regulatory tailwind: FDA Fast Track, Breakthrough Therapy, Orphan Drug + EMA Orphan + UK ILAP signals FDA confidence. CEO Benny Sørensen brings 25 years in coagulation medicine from Codiak, Alnylam, Baxter. Goldman Sachs as lead bookrunner (unusual for small biotech) signals institutional-grade conviction and quality. Pipeline: Sutacimig in Phase 3 for GT, Phase 2 for FVIID (data late 2026/early 2027). HMB-002 targeting VWD in Phase 1/2. HMB-003 preclinical, clinic initiation planned H2 2026. 🏛️ Lead underwriters: Goldman Sachs & Co., Jefferies, Evercore ISI, Wedbush PacGrow 📅 Order submission deadline: April 30, 2026 📲 Explore the deal in the Fintch app: https://t.co/CqMT1GPNnI
0
2
0
0
46
fintchone's profile image
Fintch Verified account @fintchone
🧬 New IPO: Avalyn Pharma (#AVLN) A new IPO is now available in the Fintch app. Avalyn Pharma is a U.S.-based clinical-stage biopharma company focused on rare respiratory diseases. The company develops inhaled versions of approved antifibrotic drugs, targeting pulmonary fibrosis with improved delivery and reduced systemic side effects. Bet on: inhaled drug delivery + proven molecules (pirfenidone / nintedanib) + large unmet need in IPF/PPF + potential for better tolerability vs oral therapies. 📈 Key terms – Price range: $16–18 per share – Market cap: ~$628M – Capital raised: ~$200M – Exchange: Nasdaq – Minimum investment: 100 USDT – Listing date: April 30 – Lock-up: 93 days 💰 Financials – Revenue: $0 (clinical-stage) – Total capital raised: ~$389M since inception – Fully focused on R&D and clinical development 🎯 Thesis Pulmonary fibrosis market (~$3B+) already validated by blockbuster drugs (Ofev, Esbriet) + clear side-effect limitations of oral therapies → opportunity for inhaled delivery model + potential differentiation through better safety profile + multiple shots on goal (AP01, AP02, AP03 pipeline). 🏛️ Underwriters: Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities 📅 Order submission deadline: April 29, 2026 📲 Explore the deal in the Fintch app https://t.co/CqMT1GPNnI
fintchone's tweet photo. 🧬 New IPO: Avalyn Pharma (#AVLN) A new IPO is now available in the Fintch app. Avalyn Pharma is a U.S.-based clinical-stage biopharma company focused on rare respiratory diseases. The company develops inhaled versions of approved antifibrotic drugs, targeting pulmonary fibrosis with improved delivery and reduced systemic side effects. Bet on: inhaled drug delivery + proven molecules (pirfenidone / nintedanib) + large unmet need in IPF/PPF + potential for better tolerability vs oral therapies. 📈 Key terms – Price range: $16–18 per share – Market cap: ~$628M – Capital raised: ~$200M – Exchange: Nasdaq – Minimum investment: 100 USDT – Listing date: April 30 – Lock-up: 93 days 💰 Financials – Revenue: $0 (clinical-stage) – Total capital raised: ~$389M since inception – Fully focused on R&D and clinical development 🎯 Thesis Pulmonary fibrosis market (~$3B+) already validated by blockbuster drugs (Ofev, Esbriet) + clear side-effect limitations of oral therapies → opportunity for inhaled delivery model + potential differentiation through better safety profile + multiple shots on goal (AP01, AP02, AP03 pipeline). 🏛️ Underwriters: Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities 📅 Order submission deadline: April 29, 2026 📲 Explore the deal in the Fintch app https://t.co/CqMT1GPNnI
0
1
0
0
62
fintchone's profile image
Fintch Verified account @fintchone
⚛️ New IPO: X-Energy (#XE) A new IPO is now available in the Fintch app. X-Energy is an advanced nuclear company focused on Xe-100 reactor (Gen IV, 80 MWe per unit) and TRISO-X fuel. Develops both reactor technology and fuel fabrication - broader than a pure SMR design. Bet on: advanced nuclear + AI/data center power demand + domestic fuel supply. 📈 Key terms – Price range: $16–19 per share – Market cap: ~$7.5B – Capital raised: ~$685.7–814.3M – Shares offered: 42.86M – Ticker: XE – Lock-up: 93 days 💰 Financials (2025) – Revenue + grants: $109.1M (DoE $89.4M, Commercial $14.3M) – Net loss: $389.8M – Cash: $458.9M (solid position for pre-commercial stage) 🎯 Thesis AI/data center power boom (108→426 TWh by 2030) + $2.3T market opportunity by 2050 + strategic partners (Dow, Amazon, Centrica: 11+ GWe pipeline) + TRISO-X fuel moat + DOE support ($1.2B ARDP) + repeat-deployment economics (30%+ savings potential). 🏛️ Underwriters: J.P. Morgan, Morgan Stanley, Jefferies, Moelis 📅 Order submission deadline: April 24, 2026 📲 Products now live in the Fintch app: https://t.co/CqMT1GQldg
fintchone's tweet photo. ⚛️ New IPO: X-Energy (#XE) A new IPO is now available in the Fintch app. X-Energy is an advanced nuclear company focused on Xe-100 reactor (Gen IV, 80 MWe per unit) and TRISO-X fuel. Develops both reactor technology and fuel fabrication - broader than a pure SMR design. Bet on: advanced nuclear + AI/data center power demand + domestic fuel supply. 📈 Key terms – Price range: $16–19 per share – Market cap: ~$7.5B – Capital raised: ~$685.7–814.3M – Shares offered: 42.86M – Ticker: XE – Lock-up: 93 days 💰 Financials (2025) – Revenue + grants: $109.1M (DoE $89.4M, Commercial $14.3M) – Net loss: $389.8M – Cash: $458.9M (solid position for pre-commercial stage) 🎯 Thesis AI/data center power boom (108→426 TWh by 2030) + $2.3T market opportunity by 2050 + strategic partners (Dow, Amazon, Centrica: 11+ GWe pipeline) + TRISO-X fuel moat + DOE support ($1.2B ARDP) + repeat-deployment economics (30%+ savings potential). 🏛️ Underwriters: J.P. Morgan, Morgan Stanley, Jefferies, Moelis 📅 Order submission deadline: April 24, 2026 📲 Products now live in the Fintch app: https://t.co/CqMT1GQldg
0
1
0
0
42

Last Seen Users on Sotwe

MomClipVideos's profile image
Mom Clip Fun Videos
Seen from Turkey
sawyailovex's profile image
รุ่นใหญ่วัยมันส์
Seen from Thailand
Almarieoc's profile image
Alison O'Connor
Seen from Chile
Berkak28102363's profile image
Güzel paylasim yeri ✌💏BURSA 💞
Seen from Turkey
thichlaimaybay8's profile image
mình thích lái máy bay
Diddot5's profile image
strong man
Seen from Indonesia
ThatBabyboi88's profile image
ThatGuy8891
Seen from Guatemala
turbanliannemm's profile image
Türbanlı Annem
Seen from Turkey
AlexOrt86656985's profile image
@Douma
Seen from United States
ciftsevertek's profile image
gizli eş
Seen from Turkey

Trends for you

1
#loveislandusa
Under 10K tweets
2
Pratt
Under 10K tweets
3
#TonyAwards
Under 10K tweets
4
#BaddiesUSA
Under 10K tweets
5
Bregman
Under 10K tweets
6
Philippines
Under 10K tweets
7
Raman
Under 10K tweets
8
Mormons
Under 10K tweets
9
#RHOA
Under 10K tweets
10
Aniya
Under 10K tweets

Most Popular Users

elonmusk's profile image
1
Elon Musk Verified account
@elonmusk
240.2M followers
barackobama's profile image
2
Barack Obama Verified account
@barackobama
119.3M followers
realdonaldtrump's profile image
3
Donald J. Trump Verified account
@realdonaldtrump
111.6M followers
cristiano's profile image
4
Cristiano Ronaldo Verified account
@cristiano
109M followers
narendramodi's profile image
5
Narendra Modi Verified account
@narendramodi
107M followers
rihanna's profile image
6
Rihanna Verified account
@rihanna
97.3M followers
nasa's profile image
7
NASA Verified account
@nasa
92.1M followers
justinbieber's profile image
8
Justin Bieber Verified account
@justinbieber
90.6M followers
katyperry's profile image
9
KATY PERRY Verified account
@katyperry
86.9M followers
taylorswift13's profile image
10
Taylor Swift Verified account
@taylorswift13
80.7M followers
ladygaga's profile image
11
Lady Gaga Verified account
@ladygaga
72.2M followers
kimkardashian's profile image
12
Kim Kardashian Verified account
@kimkardashian
69.4M followers
imvkohli's profile image
13
Virat Kohli Verified account
@imvkohli
68.6M followers
youtube's profile image
14
YouTube Verified account
@youtube
68.6M followers
billgates's profile image
15
Bill Gates Verified account
@billgates
63.4M followers
theellenshow's profile image
16
The Ellen Show
@theellenshow
62.5M followers
cnn's profile image
17
CNN Verified account
@cnn
61.9M followers
neymarjr's profile image
18
Neymar Jr Verified account
@neymarjr
61.2M followers
x's profile image
19
X Verified account
@x
60.9M followers
selenagomez's profile image
20
Selena Gomez Verified account
@selenagomez
60M followers